Anagliptin alleviates lipopolysaccharide-induced inflammation, apoptosis and endothelial dysfunction of lung microvascular endothelial cells

JINGLI ZHANG1 and LIXIA LIU2

1Department of Pharmacy, Taihe County People's Hospital, Fuyang, Anhui 236600; 2Department of Respiration, No. 984 Hospital, Joint Logistics Support Force of Chinese People's Liberation Army, Beijing 100094, P.R. China

Received May 24, 2021; Accepted September 7, 2021

DOI: 10.3892/etm.2021.10907

Abstract. It has been reported that dipeptidyl peptidase-4 (DPP4) inhibition protects against acute lung injury (ALI). Anagliptin is a novel selective inhibitor of DPP4 but its role in ALI has not been studied. The present study aimed to investigate the effects of anagliptin on lipopolysaccharide (LPS)-induced human pulmonary microvascular endothelial cell (HPMVEC) injury, as well as its underlying mechanism. HPMVECs were exposed to LPS in the presence or absence of anagliptin co-treatment. MTT assay was used to evaluate cell viability and nitric oxide (NO) production was detected using a commercial kit. DPP4 and pro-inflammatory cytokine expression levels, apoptosis and migration were assessed via reverse transcription-quantitative PCR, western blotting, TUNEL staining and wound healing assay, respectively. Western blot analysis was performed to assess expression levels of proteins involved in NF-κB signaling, cell apoptosis and migration, as well as high mobility group box 1 (HMGB1)/receptor for advanced glycation end products (RAGE). LPS decreased cell viability and NO production, but elevated expression of DPP4 in HPMVECs. LPS promoted pro-inflammatory cytokine expression, NF-κB activation and cell apoptosis, but inhibited cell migration and phosphorylated-AKT/endothelial NO synthase expression. Anagliptin co-treatment significantly restored all of these effects. Mechanistically, the upregulation of HMGB1/RAGE expression induced by LPS was markedly blocked by anagliptin. In conclusion, anagliptin alleviated inflammation, apoptosis and endothelial dysfunction in LPS-induced HPMVECs via modulating HMGB1/RAGE expression. These data provide a basis for use of anagliptin in ALI treatment.

Introduction

Acute lung injury (ALI) is a diffuse inflammatory reaction in the lung caused by various internal and external pathogenic factors, such as sepsis, pneumonia and trauma (1,2). ALI, which is characterized by respiratory distress, refractory hypoxemia and respiratory failure, is the primary cause of death in critically ill patients with sepsis at present (3). Bacterial infection, shock, severe trauma, sepsis and other factors induce the occurrence of ALI (4). Although the rapid development of medical technology has provided better treatment of ALI, the specific mechanism underlying its pathogenesis has not been fully elucidated and there is a lack of effective drug treatments in clinical use (5,6).

Dipeptidyl peptidase-4 (DPP4), also known as CD26, is a widely expressed serine membrane-anchored peptidase that exists on the surface of various types of cell (7). Its expression level varies from cell to cell (8,9). In different organs and tissues (such as lung, muscle and heart), DPP4 activity is associated with its presence in the microvasculature (10). Clinical and experimental research over the past 30 years has demonstrated the involvement of DPP4 in various physiological processes and diseases of immune system (11,12). Recent experimental studies have shown that DPP4 inhibition protects the lungs against severe injury and relieves associated respiratory disease, including COVID-19 caused by SARS-CoV-2 and Middle East respiratory syndrome (MERS) caused by MERS coronavirus (13-17), suggesting that DPP4 inhibitors may be used to decrease LI. A previous study proposed that the DPP4 inhibitor Saxagliptin attenuates lipopolysaccharide (LPS)-induced oxidative stress, inflammation and apoptosis (18). Another DPP4 inhibitor, vildagliptin, has been demonstrated to alleviate pulmonary fibrosis in LPS-induced LI by inhibiting endothelial-to-mesenchymal transition in pulmonary microvascular endothelial cells (PMVECs) (19).

Anagliptin, a novel selective inhibitor of DPP4, was licensed for clinical treatment of type 2 diabetes mellitus in 2012 (20). Anagliptin has been shown to alleviate inflammation and endothelial cell injury. For example, anagliptin prevents
H₂O₂-induced apoptosis of human umbilical vein endothelial cells (21). Anagliptin ameliorates high glucose-induced endothelial dysfunction via suppression of NLR family pyrin domain containing 3 inflammasome activation (22). Anagliptin inhibits neointimal hyperplasia via endothelial cell-specific modulation of superoxide dismutase-1/Ras homolog family member A/JNK signaling in the arterial wall (23). Recent comprehensive review articles indicated that DPP4 inhibitors (anagliptin, vildagliptin and sitagliptin) developed and marketed for their beneficial effects display multipotency in the management of various types of pulmonary disease (14,24). Seys et al (17) demonstrated that anagliptin displays a stronger anti-inflammatory action than sitagliptin. Another study suggested that anagliptin improves LI in mice under chronic stress, potentially by mitigating vascular inflammation (25). However, whether anagliptin relieves LPS-induced human (H) PMVEC injury remains to be elucidated.

In the present study, the effect of anagliptin on viability, inflammation, apoptosis and endothelial dysfunction of HPMVECs exposed to LPS, along with its underlying mechanism, were investigated. The present study aimed to provide a basis for the use of anagliptin in ALI treatment.

**Materials and methods**

**Cell culture and treatment.** HPMVECs were obtained from American Type Culture Collection (cat. no. CRL-3244) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS; both Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich; Merck KGaA) at 37°C with 5% CO₂. For LPS stimulation, cells were exposed to 10 ng/ml LPS (Sigma-Aldrich; Merck KGaA) at 37°C for 24 h. For anagliptin treatment, cells were exposed to various concentrations of anagliptin (1, 10, 50 or 100 µM; Sigma-Aldrich; Merck KGaA) at 37°C for 24 h. For LPS and anagliptin co-treatment, cells were sequentially exposed to 10 ng/ml LPS plus designated concentrations of anagliptin (10, 50 or 100 µM) at 37°C for 24 h.

**Cell viability assessment.** MTT assay (Beyotime Institute of Biotechnology) was utilized to detect cell viability. Briefly, HPMVECs were seeded into 96-well plates (5x10³ cells/well) and incubated at 37°C to 90% confluence. Subsequently, cells were exposed to various concentrations of anagliptin (1, 10, 50 or 100 µM) or LPS ± anagliptin for 24 h. Then, 50 µl MTT solution was added to each well and maintained for 3 h at 37°C. Cells were exposed to 150 µl DMSO and shaken on an orbital shaker for 15 min, then absorbance of each well was measured at 590 nm.

**Measurement of NO production.** The generation of NO in culture medium was measured using an NO assay kit (cat. no. S0023; Beyotime Institute of Biotechnology) in accordance with manufacturer’s protocol. Briefly, cultured cells were harvested and centrifuged at 8,000 x g for 15 min at room temperature. The culture supernatant of cells was added to 96-well plates (50 µl/well). After samples were incubated with 50 µl Griess Reagent for 3 min at room temperature, the absorbance was measured at 540 nm.

Western blot analysis. HPMVECs were lysed using RIPA buffer (Beyotime Institute of Biotechnology) containing cocktail inhibitors (Thermo Fisher Scientific, Inc.) and quantified using a Bicinchoninic Acid Protein Assay kit (Abcam). Samples (40 µg per lane) were separated by 12% SDS-PAGE and then transferred to 0.45 µM PVDF membranes (MilliporeSigma). After being blocked with 5% non-fat milk for 1.5 h at room temperature, samples were probed with primary antibodies overnight at 4°C and horseradish peroxidase-conjugated secondary antibody (1:2,000; cat. no. 7074P2; Cell Signaling Technology, Inc.) at room temperature for 2 h. Bands were visualized using ECL (Beyotime Institute of Biotechnology) and quantified with ImageJ software (Version 6.0; National Institutes of Health). The following antibodies from Abcam or Cell Signaling Technology, Inc., were used (all at a dilution of 1:1,000): Anti-DPP4 (cat. no. ab215711); anti-p65 (cat. no. ab32536); anti-Lamin B (cat. no. 17416S); anti-phosphorylated (p)-IκBα (cat. no. 2859T); anti-total (t)-IκBα (cat. no. 4812S); anti-Becl-2 (cat. no. 4223T); anti-Bax (cat. no. 5023T); anti-apoptotic protease activating factor-1 (APAF-1; cat. no. 8969T); anti-cleaved-caspase3 (cat. no. 9664T); anti-caspase3 (cat. no. 9662S); anti-AKT (cat. no. 4691T); anti-p-AKT (cat. no. 4060T); anti-endothelial NO synthase (eNOS; cat. no. 32027S); anti-inducible (i)NOS (cat. no. 20609S); anti-high mobility group box 1 (HMGB1; cat. no. 6893S); anti-receptor for advanced glycation end products (RAGE; cat. no. 6996S) and anti-GAPDH (cat. no. 5174T).

**Reverse transcription-quantitative (RT-q)PCR.** Total RNA was extracted from cells using Trizol® (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. A total of 5 µg RNA was reverse transcribed into cDNA using TaqMan One-Step RT kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Amplification was performed using SYBR Green PCR kit (Vazyme Biotech Co., Ltd) and ABI Prism 7500 sequence detector (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used for qPCR: Initial denaturation for 10 min at 95°C; followed by 40 cycles of denaturation at 95°C for 15 sec and annealing/extension at 55°C for 45 sec. The primers were as follows: DPP4 forward, 5'-TCTGCTGAACAAAGGCAA TGA-3'and reverse, 5'-CTGTTCTCACAAGAAACTGAGC-3'; tumor necrosis factor (TNF)-α forward, 5'-CATCACCACCT CCCAAACGCG-3' and reverse, 5'-CGAAGTGTTGTGTTCTTGT TGC-3'; IL-1β forward, 5'-GAGCTCGCCAGTGAATG ATG-3' and reverse, 5'-TAGTGTGTCGCCAGGAGAT CCG-3'; IL-6 forward, 5'-GTCACAGTTGCTCTCCCTGGT C-3' and reverse, 5'-CTGAGATGCGCGTGGAGATG-3'; C-C motif chemokine ligand 2 (CCL2) forward, 5'-AGATCTTGTCGTCG CCAAG-3' and reverse, 5'-GGAGTGTGGTTTGGTGTCG TCC-3'; and GAPDH, forward, 5'-GCAACCGGAGGAAAT GAATG-3' and reverse, 5'-CCCAATACGACCAAAATCG AGA-3'. Results were normalized to GAPDH expression and ∆∆Cq was used to calculate the relative change in gene expression (26).

**TUNEL staining.** TUNEL assay was used to detect the apoptosis of HPMVECs. Briefly, after cells were fixed with 4% paraformaldehyde for 30 min at room temperature, apoptosis
was detected using a TUNEL assay kit (cat. no. QIA33; Sigma-Aldrich; Merck KGaA) in accordance with the manufacturer's instructions; 50 µl TUNEL reaction mixture was added for 1 h at 37˚C. The cells were treated with DAPI (2 µg/ml) to stain the nucleus at 37˚C for 2-3 min. After washing twice with PBS, images were captured from three fields of view using an inverted fluorescence microscope (Olympus Corporation; x200 magnification).

Wound healing assay. HPMVECs were cultured in 6-well plates (5x10^5 cells/well) to 70-80% confluence. The cell surface was scratched with a 100-µl pipette tip to create an artificial wound, and medium was replaced with serum-free RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc.) containing LPS ± anagliptin and cultured for 24 h at 37˚C. Images were captured at 0 and 24 h using an inverted light microscope (magnification, x100; Olympus Corporation). The cell migration rate was calculated as follows: (Width at 0 h-width at 24 h)/width distance. The relative migration rate was obtained by normalizing to the untreated group.

Statistical analysis. Data are expressed as the mean ± standard deviation and were analyzed with SPSS 21.0 software (IBM Corp). All experiments were performed in triplicate. An unpaired Student's t-test was used for comparisons between two groups. One-way analysis of variance followed by Tukey's post hoc test was used for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.

Results

DPP4 expression is increased following LPS stimulation in HPMVECs. HPMVECs were exposed to 100 ng/ml LPS for 24 h to simulate ALI in vitro. Viability and NO production of cells significantly decreased following LPS stimulation, indicating that LPS induced HPMVEC damage (Fig. 1A and B). Furthermore, both protein and mRNA expression levels of DDP4 were significantly increased following LPS treatment of HPMVECs, suggesting that DDP4 expression is increased in LPS-induced HPMVEC injury (Fig. 1C and D).

DPP4 inhibitor anagliptin inhibits LPS-induced decrease in HPMVEC viability. Cells were stimulated with different concentrations of anagliptin (0, 1, 10, 50 and 100 µM) for 24 h. Cell viability was not altered following stimulation using different doses of anagliptin (Fig. 2A). RT-qPCR and western blot analysis were performed to detect DDP4 expression. The results revealed that anagliptin (10 µM) decreased mRNA and protein expression levels of DPP4, but this was not significantly different compared with the LPS-alone group (Fig. 2B and C). Additionally, 50 or 100 µM anagliptin significantly decreased DPP4 mRNA and protein levels (Fig. 2B and C) when compared to the LPS-alone group. The LPS-induced impaired cell viability was rescued by co-treatment with 50 and 100 µM anagliptin (Fig. 2D). These results reveal that the DPP4 inhibitor anagliptin suppressed the LPS-induced decrease in HPMVEC viability.

DPP4 inhibitor anagliptin inhibits LPS-induced inflammation and NF-κB activation in HPMVECs. LPS resulted in a significant increase in the expression levels of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6 and CCL2, but 50 and 100 µM anagliptin significantly decreased the expression of these cytokines (Fig. 3A-D). Activation of NF-κB signaling induces the inflammatory response (27). Following LSP treatment, NF-κB signaling was activated, as demonstrated by the significant increase in nuclear p65 expression and p/t-IκBα and the decrease in cytoplasmic p65 in HPMVECs (Fig. 3E). However, following stimulation with 50 or 100 µM anagliptin, nuclear p65 expression and p/t-IκBα expression were effectively suppressed, while the expression of cytoplasmic p65 was upregulated (Fig. 3E).

DPP4 inhibitor anagliptin inhibits LPS-induced apoptosis in HPMVECs. TUNEL staining was used to assess cell apoptosis. The number of apoptotic cells was significantly increased following LPS treatment, whereas 50 and 100 µM anagliptin significantly decreased this (Fig. 4A). Consistently,
LPS resulted in lower Bcl2 and higher Bax, APAF-1 and cleaved-caspase-3/caspase-3 expression compared with the untreated cells (Fig. 4B). Furthermore, 50 and 100 µM anagliptin enhanced Bcl2 but decreased Bax, APAF-1 and DPP4 expression levels were detected by western blotting and reverse transcription-quantitative PCR, respectively. (D) Cell viability was measured using MTT assay. **P<0.01 vs. untreated cells; ***P<0.001 vs. untreated cells; #P<0.05, ##P<0.01 and ###P<0.001 vs. LPS alone. HPMVEC, human pulmonary microvascular endothelial cell; LPS, lipopolysaccharide; DPP4, dipeptidyl peptidase-4.

Figure 3. Anagliptin inhibits LPS-induced inflammation and NF-κB p65 activation in HPMVECs. HPMVECs were co-treated with 100 ng/ml LPS in the presence or absence of different concentrations of anagliptin for 24 h, then mRNA levels of (A) TNF-α, IL-1β, (C) IL-6 and (D) CCL2 were measured by reverse transcription-quantitative PCR. (E) Protein expression of nuclear and cytoplasmic p65 and p/IκBα was measured by western blotting. **P<0.01 vs. untreated cells; *P<0.05, **P<0.01 and ***P<0.001 vs. LPS alone. HPMVEC, human pulmonary microvascular endothelial cell; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-α; CCL2, C-C motif chemokine ligand 2; p-, phosphorylated; t-, total.
cleaved-caspase-3/caspase-3 expression levels (Fig. 4B). These data suggest that the DPP4 inhibitor anagliptin inhibited LPS-induced apoptosis in HPMVECs.

**DPP4 inhibitor anagliptin rescues migration and endothelial function and decreases HMGB1/RAGE expression in LPS-treated HPMVECs.** Impaired endothelial cell migration and NO production are primary causes of endothelial dysfunction (28). LPS led to a significant decrease in cell migration and NO production, which were effectively rescued by treatment with 50 and 100 µM anagliptin (Fig. 5A-C). Moreover, 50 and 100 µM anagliptin significantly upregulated the decreased expression levels of p-AKT/AKT and eNOS and downregulated the increased...
expression levels of iNOS induced by LPS (Fig. 5D). The enhanced protein and mRNA expression levels of HMGB1 and RAGE induced by LPS exposure were also significantly downregulated by 50 and 100 µM anagliptin, indicating the inhibitory effect of anagliptin on HMGB1/RAGE expression levels (Fig. 5E and F).
Discussion

The alveolar capillary unit formed by PMVECs is the basic structure that maintains ventilation-perfusion balance, and is susceptible to harmful external stimuli, such as LPS (29). LPS is one of the pathogenic factors leading to abnormal microcirculation in ALI (30,31). In the present study, HPMVECs were exposed to LPS. The results showed that LPS impaired cell viability, NO production and cell migration and induced inflammation, NF-κB signaling activation and apoptosis. However, anagliptin effectively protected HPMVECs against LPS-induced injury, indicating that anagliptin may be used in the treatment of ALI.

Uncontrolled inflammation is the primary pathophysiological basis of ALI (32). The activation of NF-κB signaling induces inflammatory response (27). The present study verified that LPS induced expression of pro-inflammatory cytokines and activation of NF-κB signaling, suggesting that inflammatory responses resulted from LPS in HPMVECs. Additionally, the mechanism of ALI is associated with increased vascular endothelial apoptosis and recovery of endothelial cell viability is reported to improve ALI (33). The present study demonstrated an increase in apoptosis ratio and Bax, APAF-1 and cleaved-caspase-3 expression levels, as well as a decrease in Bcl2 expression in LPS-induced cells. As a key molecule in the intrinsic or mitochondrial pathway of apoptosis, APAF-1 leads to caspase-3 cleavage (34). Therefore, the impaired cell viability caused by LPS may induce inflammation and cell apoptosis. LPS decreased NO production and cell migration along with p-AKT and eNOS expression, but increased iNOS expression. Decreased NO, which is produced by eNOS, and impaired endothelial cell migration are linked to endothelial dysfunction, which results in an imbalance in vascular homeostasis, leading to a prothrombotic and proinflammatory condition (35,36). The AKT/eNOS pathway serves a key role in endothelial mobilization and migration (37). The present results showed that LPS caused endothelial dysfunction of HPMVECs in vitro.

Anagliptin is a novel selective inhibitor of DPP4 (38). DPP4 inhibition has been reported to prevent systemic inflammation, vascular dysfunction and end-organ damage in mice with endotoxia (39). In the study of ALI, DPP4 inhibitor saxagliptin has been reported to decrease LPS-induced oxidative stress, inflammation and apoptosis (18). Another DPP4 inhibitor, vildagliptin, ameliorates pulmonary fibrosis in LPS-induced LI by inhibiting endothelial-to-mesenchymal transition in PMVECs (19). Whether anagliptin inhibits LI is still unknown. The present study demonstrated that anagliptin recovered DPP4 expression, rescued cell viability, inhibited NF-κB activation-mediated inflammation and Bcl2/Bax/APAF-1/caspase-3-mediated apoptosis in LPS-treated HPMVECs. Furthermore, NO production and AKT/eNOS pathway-mediated cell migration, which were impaired by LPS, were all markedly rescued by anagliptin. These data indicated that anagliptin protected HPMVECs against LPS-induced injury.

HMGB1 is a typical damage-associated molecular pattern protein that exerts its biological activity primarily by binding to RAGE. Anagliptin has been verified to suppress HMGB1 expression (40,41). Notably, LPS binds to HMGB1 to serve a key role in endothelial dysfunction (42). The present results showed that LPS significantly upregulated HMGB1 and RAGE expression levels, but anagliptin effectively inhibited this effect. As a result, it was speculated that anagliptin may exert its beneficial role in LPS-induced HPMVEC injury via inhibiting LPS-mediated HMGB1/RAGE upregulation.

To the best of our knowledge, the present study is the first to investigate the effects of anagliptin on LPS-induced ALI. Anagliptin alleviated LPS-induced HPMVEC injury by the decreasing inflammation, apoptosis and endothelial dysfunction via inhibiting LPS-mediated HMGB1/RAGE upregulation. However, the specific mechanisms involved in the action of anagliptin need to be clarified in subsequent experiments. In addition, safety evaluation and pharmacokinetic studies of anagliptin should be performed in future. These are limitations of the present study and comprehensive and in-depth analysis will be conducted in future to provide further evidence for the treatment of ALI using anagliptin.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Author’s contributions

JZ and LL contributed to study conception and design and acquisition, analysis and interpretation of data. JZ drafted the manuscript. LL revised the manuscript critically for important intellectual content. Both authors have read and approved the final manuscript. JZ and LL confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Dushianthan A, Grocott MP, Postle AD and Cusack R: Acute respiratory distress syndrome and acute lung injury. Postgrad Med J 87: 612-622, 2011.
2. Ali H, Khan A, Ali J, Ullah H, Khan A, Ali H, Irshad N and Khan S: Attenuation of LPS-induced acute lung injury by continentalic acid in rodents through inhibition of inflammatory mediators correlates with increased Nrf2 protein expression. BMC Pharmacol Toxicol 21: 81, 2020.
3. Butt Y, Kurdowska A and Allen TC: Acute Lung Injury: A Clinical and Molecular Review. Arch Pathol Lab Med 140: 345-350, 2016.
4. Hughes KT and Beasley MB: Pulmonary Manifestations of Acute Lung Injury: More Than Just Diffuse Alveolar Damage. Arch Pathol Lab Med 141: 916-922, 2017.

5. Hu Q, Wang Q, Han C and Yang Y: Sulfatide attenuates inflammation and oxidative stress in sepsis-induced acute lung injury by downregulating KGN1 expression. Mol Med Rep 22: 4298-4306, 2020.

6. Schmidt GA: Managing Acute Lung Injury. Clin Chest Med 37: 647-658, 2016.

7. Piao L, Li Y, Narisawa M, Shen X and Cheng XW: Role of Dipeptidyl Peptidase-4 in Atherosclerotic Cardiovascular Disease in Humans and Animals with Chronic Stress. Int Heart J 62: 470-478, 2021.

8. Yip HK, Lee MS, Li YC, Shao PL, Chiang JY, Sung PH, Yang CH and Chen KH: Dipeptidyl Peptidase-4 deficiency effectively protects the brain and neurological function in rodent after acute Hemorrhagic Stroke. Int J Biol Sci 16: 3116-3132, 2020.

9. Lee M, Shin E, Bae C, Cho J, Lee YJ, Lee YH, Lee BW, Kang ES and Cha BS: Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL-receptor-mediated lipopolysaccharide via modulating hepatic dipeptidyl peptidase-4 expression. Sci Rep 10: 19429, 2020.

10. Klemm C, Wagner L, Stephan M and von Hörsten S: Cut to the chase: A review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clin Exp Immunol 185: 1-16, 2021.

11. Zhao Y: CD26 in autoimmune diseases: The other side of 'moonlight protein’. Int Immunopharmacoph 75: 105757, 2019.

12. Wang X, Ke J, Zhu YJ, Cao B, Yin RL, Wang Y, Wei LL, Zhang LJ, Yang LY and Zhao D: Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin ameliorates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway. Cell Death Discov 7: 236, 2021.

13. Kawasaki T, Chen W, Htwe YM, Asselin J, Janssens W, Joos GF, Bracke KR, Haagmans BL and Brusselle GG: DPP4, a therapeutic target in lung disease. Expert Opin Ther Targets 24: 147-153, 2020.

14. Seys LM, Widago W, Verhamme FM, Kleinjans J, Janssens W, Joos GF, Bracke KR, Haagmans BL and Brusselle GG: DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients. Clin Infect Dis 66: 45-53, 2018.

15. Guo K and Jin F: Dipeptidyl peptidase-4 (DPP4) inhibitor saxagliptin alleviates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 315: L834-L845, 2018.

16. Solerte SB, Di Sabatino A, Galli M and Fiorina P: Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol 57: 779-783, 2020.

17. Strollo R and Pozzilli P: DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19? Diabetes Metab Res Rev 36: e3330, 2020.

18. Zou H, Zhu N and Li S: The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease. Expert Opin Ther Targets 24: 147-153, 2020.

19. Roussel R, Duran-Garcia S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz J et al.: Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT1-Study. Diabetes Obes Metab 21: 781-790, 2019.

20. Zhao X, Sun J, Chen Y, Su W, Shan H, Li Y, Wang Y, Zheng N, Shan H and Zhang H: InCRIA PEAR Promotes Lung Fibroblast Activation and Fibrosis by Targeting miR-138 to Regulate the YAP1-Twist Axis. Mol Ther 26: 2206-2217, 2018.

21. Jiang T, Jiang D, Zhang L, Ding M and Zhou H: Anagliptinameliorates high glucose- induced endothelial dysfunction via suppression of NLRF3 inflammasome activation mediated by SIRT1. Mol Immunol 107: 54-60, 2020.

22. Li Q, Zhang M, Xuan L, Liu Y and Chen C: Anagliptin inhibits neointimal hyperplasia after balloon injury via endothelial cell-specific modulation of SOD-1/RhoA/JNK signaling in the arterial wall. Free Radic Biol Med 121: 105-116, 2018.